CN103285172A - Chinese medicament composition for treating myoma of uterus and endometrial cancer and application thereof - Google Patents
Chinese medicament composition for treating myoma of uterus and endometrial cancer and application thereof Download PDFInfo
- Publication number
- CN103285172A CN103285172A CN2013101975038A CN201310197503A CN103285172A CN 103285172 A CN103285172 A CN 103285172A CN 2013101975038 A CN2013101975038 A CN 2013101975038A CN 201310197503 A CN201310197503 A CN 201310197503A CN 103285172 A CN103285172 A CN 103285172A
- Authority
- CN
- China
- Prior art keywords
- parts
- herba
- chinese medicine
- medicine composition
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a Chinese medicament composition for treating myoma of uterus and endometrial cancer and an application of the Chinese medicament composition. The Chinese medicament composition is prepared from the following raw medicaments in parts by weight: 15 to 30 parts of lithospermum, 15 to 30 parts of oldenlandia diffusa, 10 to 20 parts of spica prunellae, 10 to 20 parts of eclipta, 15 to 30 parts of gypsum rubrum and 10-20 parts of herba scutellariae barbatae. The Chinese medicament composition has functions in clearing heat and promoting dieresis, dissipating stasis and stopping bleeding, calming liver and tonifying kidney and breaking channel and eliminating tumors, and has remarkable curative effect on myoma of uterus and endometrial cancer; furthermore, as the composition is prepared from a small amount of raw medicaments, the composition is easy to prepare, low in cost, free from toxic and side effects and is easy to be accepted by patients.
Description
Technical field
The present invention relates to a kind of is the Chinese patent medicine of feedstock production with the Chinese herbal medicine, specifically, is a kind of Chinese medicine composition and application thereof for the treatment of hysteromyoma and carcinoma of endometrium.
Background technology
Hysteromyoma claims leiomyoma of uterus again, is one of gynecological clinic commonly encountered diseases and susceptible disease.Its sickness rate occupy first of gynecological's benign tumor, accounts for 90%.Though primary disease is threat to life not, can cause menorrhagia, cause hemorrhagic anemia, what have also can cause miscarriage, infertility.Hysteromyoma belongs to traditional Chinese medical science “ mass in the abdomen " category, its pathogenesis is visceral dysfunction, causes tangible heresy such as blood stasis, expectorant knot, turbid damp to be given birth in succession, ties in the uterus, with the passing of time Cheng Disorder stops in the Yu mass resulting from the blood stasis knot, Chong and Ren channel disorder, the stasis of blood is not gone new difficult giving birth to, and stasis of blood knot is day big.Therefore, the generation of hysteromyoma is total because being the stasis of blood.In evolution took place for it, the continuous cloudy blood of consume consumed healthy energy again, more increases the weight of the existence of " stasis of blood ", cause and effect alternate thus, and vicious cycle makes the prolonged difficulty of disease more.Patients with uterine myoma shows as the body of the tongue dimness more clinically, the tongue body enlargement, indentations at the margin of the tongue, arteries and veins be how heavy thin, more because patient's menorrhagia, menostaxis, often with lower abdomen weigh down expand, lassitude loin and legs, dizzy symptom such as weak, this is resembling of the deficiency of vital energy.Just because of deficiency in origin, then standard card shows as fixture block in the blood, the time have stomachache, tongue to have the stasis of blood of petechia ecchymosis to resemble.The prolonged illness deficiency of vital energy is involved yang deficiency, water-damp not being transformed, and the poly-wet expectorant that is, expectorant is turbid gluing, phlegm and blood stasis.
Carcinoma of endometrium is one of three common big malignant tumor of female genital tract.In recent years, along with the aging of growth in the living standard, population, the extensive use of hormone replacement therapy, the sickness rate of carcinoma of endometrium worldwide is ascendant trend year by year.Early stage carcinoma of endometrium takes operation or chemotherapy effect good, but the carcinoma of endometrium prognosis of late period or recurrence is very poor, the main palliative therapy that adopts based on chemotherapy.The toxicity of chemotherapy and multidrug resistance are the main causes that influences chemotherapeutic efficacy, are the key factors of improving carcinoma of endometrium patient prognosis so explore more efficiently Therapeutic Method.Along with the extensive use in the Chinese medicine research field of cellular biology of tumor and molecular biology research technology, the Chinese medicine characteristics of high efficiency and low toxicity causes concern day by day, and Chinese medicine develops, improves aspects such as symptom and sign and raising life quality at the control conditions of patients advantage day by day manifests.Therefore, excavation has the Chinese medicine of anti-carcinoma of endometrium effect and illustrates its dependent interaction mechanism has become current research focus.
Chinese periodical " Zhejiang clinical medicine " the 5th the 9th phase of volume of JIUYUE in 2003, the paper that name is called " Radix Arnebiae (Radix Lithospermi) dispersing tumor cracked ends soup treatment climacteric hysteromyoma 52 examples " discloses a kind of Radix Arnebiae (Radix Lithospermi) dispersing tumor cracked ends soup for the treatment of hysteromyoma, is made by Radix Arnebiae (Radix Lithospermi) 30g, Herba Hedyotidis Diffusae 30g, Spica Prunellae 30g, Herba Ecliptae 30g, Concha Ostreae 30g, Fructus Ligustri Lucidi 12g, each 12g of dahsiao-ch'i, Herba Salviae Chinensis 15g; 2008 the 15th the 7th phases of volume of Chinese periodical " Chinese Chinese medicine information magazine ", name is called " blood clot dispersing and tumor eliminating granule treatment hysteromyoma 52 routine observation of curative effect " and discloses a kind of blood clot dispersing and tumor eliminating granule for the treatment of hysteromyoma, is made by rhizoma sparganic 10g, Rhizoma Curcumae 10g, Hirudo 6g, Cortex Moutan 10g, Poria 10g, Spica Prunellae 10g, Herba Portulacae 15g, living Rhizoma Osmundae 12g, Herba Scutellariae Barbatae 30g etc.; 2009 the 7th the 8th phases of volume of Chinese periodical " Chinese Chinese medicine ", name is called " changing disease dispersing tumor soup treatment hysteromyoma 72 examples ", disclose a kind of change disease dispersing tumor soup for the treatment of hysteromyoma, medicine consists of: Radix Angelicae Sinensis 10g, stir-baked SQUAMA MANITIS 15g (being decocted first), Radix Paeoniae Rubra l0g, Semen Persicae 10g, Flos Carthami 6g, Radix Salviae Miltiorrhizae 18g, Concha Ostreae 30g (being decocted first), Radix Astragali 30g, Herba Scutellariae Barbatae 30g, Herba Hedyotidis Diffusae 30g, Spica Prunellae 15g, Thallus Laminariae (Thallus Eckloniae) 15g.But the Chinese medicine flavour of a drug number of above-mentioned treatment hysteromyoma is more, is not easy to preparation, and cost is also higher, therefore need badly a kind of flavour of a drug number less, be convenient to prepare, abundant raw materials is easy to get and the Chinese medicine composition of therapeutic effect obvious treatment hysteromyoma.
Summary of the invention
The objective of the invention is at deficiency of the prior art, a kind of Chinese medicine composition for the treatment of hysteromyoma and carcinoma of endometrium is provided.
One purpose more of the present invention is that the purposes of above-mentioned Chinese medicine composition is provided.
For achieving the above object, the technical scheme taked of the present invention is:
A kind of Chinese medicine composition for the treatment of hysteromyoma and carcinoma of endometrium, it is to be made by following bulk drugs: Radix Arnebiae (Radix Lithospermi) 15-30 part, Herba Hedyotidis Diffusae 15-30 part, Spica Prunellae 10-20 part, Herba Ecliptae 10-20 part, Mirabilitum crystallina 15-30 part, Herba Scutellariae Barbatae 10-20 part.
Preferably, described Chinese medicine composition is to be made by following bulk drugs: Radix Arnebiae (Radix Lithospermi) 20-30 part, Herba Hedyotidis Diffusae 20-30 part, Spica Prunellae 10-15 part, Herba Ecliptae 10-15 part, Mirabilitum crystallina 20-30 part, Herba Scutellariae Barbatae 10-15 part.
Preferably, described Chinese medicine composition is to be made by following bulk drugs: 30 parts of Radix Arnebiae (Radix Lithospermi)s, 30 parts of Herba Hedyotidis Diffusaes, 12 parts of Spica Prunellaes, 12 parts of Herba Ecliptaes, 30 parts of Mirabilitum crystallinas, 12 parts of Herba Scutellariae Barbataes.
The medicament of described Chinese medicine composition is capsule, granule, tablet, oral liquid, mixture or syrup.
For realizing above-mentioned second purpose, the technical scheme that the present invention takes is:
The as above application of arbitrary described Chinese medicine composition in the medicine of preparation treatment hysteromyoma and/or carcinoma of endometrium.
Need to prove that described Mirabilitum crystallina is the Ore of monoclinic system Sulfates mineral trigonal system carbonate mineral calcite Calcite, main product in East China, ground such as Central-South and Sichuan, Henan.Colourless, the transparent or white cleavage shape of multiselect block is medicinal after the calcite extraction, practise to claim " Calcitum rubrum ", white with the big color of piece, matter is loose, fibrous, not have assorted stone person be good.Specifically can consult: (1) Yang Weiping, Xia Tonghang chief editor. newly organized Chinese herbal medicine collection of illustrative plates and common prescription. Guizhou science and technology publishing house, 2010.01; (2) Yang Zhonglin chief editor. the science of Chinese drug processing. Chinese Medicine science and technology publishing house, 2008.6.
Chinese medicine composition advantage of the present invention is:
1, have clearing away heat-damp and promoting diuresis, the dissipating blood stasis hemostasis, the suppressing the hyperactive liver kidney tonifying, the effect of cracked ends dispersing tumor, the treatment hysteromyoma is evident in efficacy, can make spanomenorrhea, until menopause;
2, can significantly suppress the tumor growth of carcinoma of endometrium mice, can be used for the control of carcinoma of endometrium;
3, the flavour of a drug number is few, is convenient to preparation, and abundant raw materials is easy to get, and cost is low, is suitable for promoting;
4, made by pure Chinese medicine, have no side effect, be easy to be accepted by the patient.
The specific embodiment
Below the specific embodiment provided by the invention is elaborated.
The preparation (one) of embodiment 1 Chinese medicine composition of the present invention
30 parts of Radix Arnebiae (Radix Lithospermi)s, 30 parts of Herba Hedyotidis Diffusaes, 12 parts of Spica Prunellaes, 12 parts of Herba Ecliptaes, 30 parts of Mirabilitum crystallinas, 12 parts of Herba Scutellariae Barbataes, conventional method decocts.
The preparation (two) of embodiment 2 Chinese medicine compositions of the present invention
15 parts of Radix Arnebiae (Radix Lithospermi)s, 30 parts of Herba Hedyotidis Diffusaes, 10 parts of Spica Prunellaes, 20 parts of Herba Ecliptaes, 15 parts of Mirabilitum crystallinas, 20 parts of Herba Scutellariae Barbataes, conventional method decocts.
The preparation (three) of embodiment 3 Chinese medicine compositions of the present invention
30 parts of Radix Arnebiae (Radix Lithospermi)s, 15 parts of Herba Hedyotidis Diffusaes, 20 parts of Spica Prunellaes, 10 parts of Herba Ecliptaes, 30 parts of Mirabilitum crystallinas, 10 parts of Herba Scutellariae Barbataes, conventional method decocts.
The preparation (four) of embodiment 4 Chinese medicine compositions of the present invention
15 parts of Radix Arnebiae (Radix Lithospermi)s, 15 parts of Herba Hedyotidis Diffusaes, 20 parts of Spica Prunellaes, 20 parts of Herba Ecliptaes, 15 parts of Mirabilitum crystallinas, 10 parts of Herba Scutellariae Barbataes, conventional method decocts.
The preparation (five) of embodiment 5 Chinese medicine compositions of the present invention
30 parts of Radix Arnebiae (Radix Lithospermi)s, 15 parts of Herba Hedyotidis Diffusaes, 10 parts of Spica Prunellaes, 20 parts of Herba Ecliptaes, 30 parts of Mirabilitum crystallinas, 10 parts of Herba Scutellariae Barbataes, conventional method decocts.
The preparation (six) of embodiment 6 Chinese medicine compositions of the present invention
30 parts of Radix Arnebiae (Radix Lithospermi)s, 30 parts of Herba Hedyotidis Diffusaes, 20 parts of Spica Prunellaes, 10 parts of Herba Ecliptaes, 15 parts of Mirabilitum crystallinas, 10 parts of Herba Scutellariae Barbataes, conventional method decocts.
The preparation (seven) of embodiment 7 Chinese medicine compositions of the present invention
20 parts of Radix Arnebiae (Radix Lithospermi)s, 30 parts of Herba Hedyotidis Diffusaes, 10 parts of Spica Prunellaes, 15 parts of Herba Ecliptaes, 20 parts of Mirabilitum crystallinas, 15 parts of Herba Scutellariae Barbataes, conventional method decocts.
The preparation (eight) of embodiment 8 Chinese medicine compositions of the present invention
30 parts of Radix Arnebiae (Radix Lithospermi)s, 20 parts of Herba Hedyotidis Diffusaes, 15 parts of Spica Prunellaes, 10 parts of Herba Ecliptaes, 30 parts of Mirabilitum crystallinas, 10 parts of Herba Scutellariae Barbataes, conventional method decocts.
The preparation (nine) of embodiment 9 Chinese medicine compositions of the present invention
20 parts of Radix Arnebiae (Radix Lithospermi)s, 30 parts of Herba Hedyotidis Diffusaes, 15 parts of Spica Prunellaes, 15 parts of Herba Ecliptaes, 20 parts of Mirabilitum crystallinas, 10 parts of Herba Scutellariae Barbataes, conventional method decocts.
The preparation (ten) of embodiment 10 Chinese medicine compositions of the present invention
30 parts of Radix Arnebiae (Radix Lithospermi)s, 20 parts of Herba Hedyotidis Diffusaes, 15 parts of Spica Prunellaes, 15 parts of Herba Ecliptaes, 20 parts of Mirabilitum crystallinas, 10 parts of Herba Scutellariae Barbataes, conventional method decocts.
Need to prove that it is the manufacture method of Chinese medicine decoction routine that the described conventional method of embodiment 1-10 decocts, and is about to described crude drug and decocts with water into decoction.
The preparation of embodiment 11 Chinese medicine composition tablets/capsules of the present invention
Get the arbitrary described medicine of embodiment 1-10, add 8-12 times of water gaging, decocted 1-3 hour, leach medicine juice.Add 10 times of water gagings again, decocted 1.5-2.5 hour, leach medicine juice, merge the secondary decocting liquid, leave standstill, the leaching supernatant concentrates, and puts coldly, adds 2.5 times of amounts of concentrated solution ethanol, stirs precipitation and spends the night.Get supernatant, be concentrated into thick extractum; Add pharmaceutical aids, vacuum drying is pulverized and is granulated, and is pressed into tablet or fills encapsulated.
The preparation of embodiment 12 Chinese medicine composition composition granules of the present invention
Get the arbitrary described medicine of embodiment 1-10, add 8-10 times of water gaging, decocted 2.5-3.5 hour, leach medicine juice.Add 10 times of water gagings again, decocted 2 hours, leach medicine juice, merge the secondary decocting liquid, leave standstill, the leaching supernatant concentrates, and puts coldly, adds 2 times of amounts of concentrated solution ethanol, stirs precipitation and spends the night.Get supernatant, be concentrated into thick extractum; Add suitable pharmaceutical aids, granulate, drying, granulate gets the 20g granule, packing 10g/ bag.
The preparation of embodiment 13 Chinese medicine composition mixture/oral liquid of the present invention/syrups
Get the arbitrary described medicine of embodiment 1-10, add 8-10 times of water gaging, decocted 3 hours, leach medicine juice.Add 8 times of water gagings again, decocted 2 hours, leach medicine juice, merge the secondary decocting liquid, leave standstill, the leaching supernatant concentrates, and puts coldly, adds 2 times of amounts of concentrated solution ethanol, stirs precipitation and spends the night.Get supernatant, be concentrated into thick extractum; Add suitable pharmaceutical aids, make mixture, oral liquid or syrup.
The clinical trial of embodiment 14 traditional Chinese medicine composition for treating hysteromyoma of the present invention
1 physical data
156 routine climacteric womens, age 45-52 year, the course of disease 1 month-6 years, single-shot person 66 examples, multiple person 90 examples; Muscular tumor is from 2.1cm * 2.6cm * 2.9cm-11cm * 9.8cm * 8.7cm.The cervical smear inspection is all negative.Be divided into three groups at random: treatment group, matched group one and matched group two, every group of 52 examples.
2 Therapeutic Method
The treatment group is taken the Chinese medicine composition of embodiment 1 preparation, decocts to containing crude drug amount 0.25g/mL, and 1 dose of every day, 1 dose is 10mL; Matched group one is taken Radix Arnebiae (Radix Lithospermi) dispersing tumor cracked ends soup of the prior art: 30 parts of Radix Arnebiae (Radix Lithospermi)s, 30 parts of Herba Hedyotidis Diffusaes, 30 parts of Spica Prunellaes, 30 parts of Herba Ecliptaes, 30 parts of Concha Ostreae, 12 parts of Fructus Ligustri Lucidi, each 12 parts of dahsiao-ch'is, 15 parts of Herba Salviae Chinensiss, decoct to containing crude drug amount 0.25g/mL, 1 dose of every day, 1 dose is 10mL; Matched group two is taken Chinese medicine composition: 30 parts of Radix Arnebiae (Radix Lithospermi)s, 30 parts of Herba Hedyotidis Diffusaes, 30 parts of Spica Prunellaes, 30 parts of Herba Ecliptaes, 30 parts of Concha Ostreae, decoct to containing crude drug amount 0.25g/mL, and 1 dose of every day, 1 dose is 10mL.3 months is 1 course for the treatment of, treats 3 courses for the treatment of.After treatment finishes, ultrasound diagnosis hysteromyoma situation, (1) is effective: hysteromyoma complete obiteration or dwindle more than 1/2; (2) produce effects: hysteromyoma dwindles below 1/2; (3) invalid: the hysteromyoma no change.Menstrual blood volume difference before and after patient's readme treatment, (1) is effective: menopause or menstrual blood volume reduce about more than 1/2; (2) produce effects: menstrual blood volume reduces about below 1/2; (3) invalid: the menstrual blood volume no change.
3 therapeutic outcomes
Hysteromyoma size improvement situation sees Table 1 after 3 courses for the treatment of, and the therapeutic effect of menstrual blood volume is seen Table 2.
Table 1 Chinese medicine composition of the present invention is to the influence of hysteromyoma size
Table 2 Chinese medicine composition of the present invention is to the influence of menstrual blood volume
From The above results as can be seen, Chinese medicine composition of the present invention is compared with the Radix Arnebiae (Radix Lithospermi) dispersing tumor cracked ends soup of prior art, and total effective rate is suitable, and the routine number of eliminating hysteromyoma fully after 3 courses for the treatment of is apparently higher than Radix Arnebiae (Radix Lithospermi) dispersing tumor cracked ends soup, and effect is very remarkable; Simultaneously, Chinese medicine composition total effective rate of the present invention is significantly higher than matched group two, be better than by 30 parts of Radix Arnebiae (Radix Lithospermi)s, 30 parts of Herba Hedyotidis Diffusaes, 30 parts of Spica Prunellaes, 30 parts of Herba Ecliptaes, 30 parts of Chinese medicine compositions of forming of Concha Ostreae, illustrate that the present invention adopts Mirabilitum crystallina, Herba Scutellariae Barbatae compatibility Radix Arnebiae (Radix Lithospermi), Herba Hedyotidis Diffusae, Spica Prunellae, Herba Ecliptae, can reach clearing away heat-damp and promoting diuresis, dissipating blood stasis hemostasis, suppressing the hyperactive liver kidney tonifying, the effect of cracked ends dispersing tumor significantly promotes drug effect; Moreover Chinese medicine composition of the present invention can make menstrual blood volume significantly reduce than matched group one and matched group two.
The animal experiment of embodiment 15 traditional Chinese medicine composition for treating carcinomas of endometrium of the present invention
1 material and method
1.1 material
People's carcinoma of endometrium Ishikawa cell strain: Shanghai Communications University First People's Hospital preserves; BABL/C mice (4-6 age in week).
1.2 mouse model is set up
People's carcinoma of endometrium Ishikawa cell is cultivated in 1640 (containing 10% FBS) culture medium and is gone down to posterity, and gets well-grown cell after trypsinization, with the counting chamber counting, cell density is adjusted to 25 * 10
7/ ml.Get 40 BABL/C mices, with 25 * 10 of 0.2ml
7/ ml Ishikawa cell inoculation is subcutaneous in every mouse back, begins inhibition test behind the inoculation 8d.
1.3 inhibition test
Modeling success tumor-bearing mice is divided into 3 groups, 20 every group at random: normal saline group (negative control), intraperitoneal injection of saline 2ml/, every day 1 time, 20d continuously; Chinese drug-treated group gives embodiment the decoction of 1 preparation, decocts to containing crude drug amount 0.25g/mL, and 2ml/ only irritates stomach, every day 2 times, 20d continuously; Cisplatin group (positive control) gives cisplatin lumbar injection 0.2ml/ only (according to the 2mg/kg administration), every day 1 time, 20d continuously.Observe the life quality situation of respectively organizing mice, use vernier caliper measurement tumor major diameter (L) and minor axis (W) behind the 20d, and press gross tumor volume computing formula V=L * W
2/ 2 calculate gross tumor volume.Weighing tumor in addition is heavy, calculates tumour inhibiting rate (IR), tumour inhibiting rate=[(normal saline group tumor weight-experimental group tumor weight)/normal saline group tumor weight] * 100%.
1.4 data analysis
All The data
± S represents, the LSD-t check of adopting the variance analysis of multisample mean comparison and comparing in twos, and data analysis adopts SPSS 14.0 statistical softwares to finish, and is that difference has statistical significance with P＜0.05.
2 results
2.1 respectively organize medicine to the influence of mouse subcutaneous transplanting tumor growth volume
20d after the Drug therapy, normal saline group transplanted tumor continues to grow up, and Chinese drug-treated group and cisplatin group transplanted tumor diminish, and see Table 3.
Table 3 mouse subcutaneous transplanting tumor growth volume
Annotate: compare * P＜0.05 with the normal saline group.
2.2 respectively organize the medicine influence heavy to mouse subcutaneous transplanting tumor tumor
After experiment finishes, take by weighing and respectively organize the transplanted tumor tumor heavily, each medication group tumor weight average is lower than normal saline group (P＜0.05), but the different not statistically significant of the tumor method of double differences between each medication group sees Table 4.
Heavy and the tumour inhibiting rate of table 4 mice-transplanted tumor
Annotate: compare * P＜0.05 with the normal saline group.
Above-mentioned result of the test shows that Chinese medicine composition of the present invention can significantly suppress the carcinoma of endometrium growth of tumor, and effect is suitable with the Western medicine cisplatin.
The above only is preferred implementation of the present invention; should be pointed out that for those skilled in the art, under the prerequisite that does not break away from the inventive method; can also make some improvement and replenish, these improvement and replenish and also should be considered as protection scope of the present invention.
Claims (5)
1. Chinese medicine composition for the treatment of hysteromyoma and carcinoma of endometrium, it is characterized in that it is to be made by following bulk drugs: Radix Arnebiae (Radix Lithospermi) 15-30 part, Herba Hedyotidis Diffusae 15-30 part, Spica Prunellae 10-20 part, Herba Ecliptae 10-20 part, Mirabilitum crystallina 15-30 part, Herba Scutellariae Barbatae 10-20 part.
2. Chinese medicine composition according to claim 1, it is characterized in that it is to be made by following bulk drugs: Radix Arnebiae (Radix Lithospermi) 20-30 part, Herba Hedyotidis Diffusae 20-30 part, Spica Prunellae 10-15 part, Herba Ecliptae 10-15 part, Mirabilitum crystallina 20-30 part, Herba Scutellariae Barbatae 10-15 part.
3. Chinese medicine composition according to claim 2 is characterized in that, it is to be made by following bulk drugs: 30 parts of Radix Arnebiae (Radix Lithospermi)s, 30 parts of Herba Hedyotidis Diffusaes, 12 parts of Spica Prunellaes, 12 parts of Herba Ecliptaes, 30 parts of Mirabilitum crystallinas, 12 parts of Herba Scutellariae Barbataes.
4. according to the arbitrary described Chinese medicine composition of claim 1-3, it is characterized in that the medicament of described Chinese medicine composition is capsule, granule, tablet, oral liquid, mixture or syrup.
5. the application of the arbitrary described Chinese medicine composition of claim 1-3 in the medicine of preparation treatment hysteromyoma and/or carcinoma of endometrium.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310197503.8A CN103285172B (en) | 2013-05-24 | 2013-05-24 | Chinese medicament composition for treating myoma of uterus and endometrial cancer and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310197503.8A CN103285172B (en) | 2013-05-24 | 2013-05-24 | Chinese medicament composition for treating myoma of uterus and endometrial cancer and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103285172A true CN103285172A (en) | 2013-09-11 |
| CN103285172B CN103285172B (en) | 2014-06-25 |
Family
ID=49087061
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310197503.8A Active CN103285172B (en) | 2013-05-24 | 2013-05-24 | Chinese medicament composition for treating myoma of uterus and endometrial cancer and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103285172B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103721223A (en) * | 2013-12-14 | 2014-04-16 | 郑明立 | Medicine for treating functional uterine bleeding and preparation method thereof |
| CN111643547A (en) * | 2020-06-22 | 2020-09-11 | 许玉良 | Composition and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1706434A (en) * | 2005-04-21 | 2005-12-14 | 张继成 | Chinese medicine composition for treating various kinds of inflammation and cyst |
| CN102600278A (en) * | 2012-03-05 | 2012-07-25 | 丛月英 | Chinese medicament for treating uterine fibroid |
-
2013
- 2013-05-24 CN CN201310197503.8A patent/CN103285172B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1706434A (en) * | 2005-04-21 | 2005-12-14 | 张继成 | Chinese medicine composition for treating various kinds of inflammation and cyst |
| CN102600278A (en) * | 2012-03-05 | 2012-07-25 | 丛月英 | Chinese medicament for treating uterine fibroid |
Non-Patent Citations (3)
| Title |
|---|
| 朱南孙: "子宫肌瘤诊治心得", <<上海中医药大学学报>>, vol. 22, no. 6, 30 November 2008 (2008-11-30), pages 1 - 2 * |
| 裴红鸽等: "绝经缩瘤法治疗围绝经期子宫肌瘤思路探讨", <<辽宁中医杂志>>, vol. 36, no. 8, 31 August 2008 (2008-08-31), pages 1171 - 1172 * |
| 赵莉等: "朱南孙治疗子宫肌瘤经验", <<上海中医药杂志>>, vol. 44, no. 6, 30 June 2010 (2010-06-30) * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103721223A (en) * | 2013-12-14 | 2014-04-16 | 郑明立 | Medicine for treating functional uterine bleeding and preparation method thereof |
| CN111643547A (en) * | 2020-06-22 | 2020-09-11 | 许玉良 | Composition and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103285172B (en) | 2014-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102283867B (en) | Traditional Chinese medicine composition for treating cancer | |
| CN100490789C (en) | Enteric coated Chinese medicinal capsule for treating cancer and preparation method thereof | |
| CN104352608A (en) | Traditional Chinese medicine capable of benefiting qi, activating blood circulation, softening hardness, dissipating stagnation, realizing detoxification and relieving pain as well as preparation method thereof | |
| CN102210836A (en) | Application of Chinese medicinal composition in preparation of medicine for treating stomach cancer | |
| CN102008650A (en) | Compound traditional Chinese medicine preparation for treating tumors and preparation method thereof | |
| Lin et al. | Herb pairs containing Curcumae Rhizoma (Ezhu): A review of bio-active constituents, compatibility effects and t-copula function analysis | |
| CN105769889A (en) | Application of ginsenoside Ro in preparation of antitumor drugs | |
| CN103463554B (en) | A kind of treat malignant tumor pharmaceutical composition and preparation method and purposes | |
| CN103285172B (en) | Chinese medicament composition for treating myoma of uterus and endometrial cancer and application thereof | |
| CN108186794B (en) | Traditional Chinese medicine composition for treating lung cancer and preparation method and application thereof | |
| CN103550718B (en) | A kind of Chinese medicine composition for the treatment of pulmonary carcinoma | |
| CN103394002B (en) | Medicinal composition for treating cutaneous pruritus as well as preparation method and application thereof | |
| CN102908443B (en) | Medicinal composition for therapy or adjuvant therapy of aids, preparation method of medicinal composition and application of medicinal composition | |
| CN102225182B (en) | Traditional Chinese preparation capable of inhibiting tumor and enhancing immunity and preparation method thereof | |
| CN104324316A (en) | Application of traditional Chinese medicine composition to prepare medicines treating colorectal cancer | |
| CN101912478B (en) | Medicinal composition for treating female menopathy | |
| CN105596890A (en) | Method for preparing traditional Chinese medicine composition for treating lung cancer | |
| CN101675961B (en) | A medicinal preparation for treating breast cancer and preparation method thereof | |
| CN105982906A (en) | Application of 20(R)-ginsenoside Rg3 in preparing medicines or health products capable of alleviating or/and treating rheumatoid diseases and medicines | |
| CN102430054B (en) | Applications of traditional Chinese medicinal compound preparation for removing toxicity, resisting cancer, activating blood and dissipating mass | |
| CN103948859A (en) | Anti-tumor traditional Chinese medicine compound preparation as well as preparation method and application thereof | |
| CN105521370A (en) | Pharmaceutical preparation for treating colon cancer and application thereof | |
| CN102106909B (en) | Fuzheng Zengxiao Anti-cancer Chinese herbal medicine and preparation method thereof | |
| CN100348249C (en) | Method for preparing medicine for treating malignancy disease and use thereof | |
| CN105434533A (en) | Traditional Chinese medicine composition for treating liver cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |